Theranos

Builder.ai raised $450M with AI that was mostly humans. Here's how pitch decks became the product.

When massive funding rounds mask a complete absence of product-market fit — and the employees who pay the price.

We explore the structural parallels between high-control groups and the ESG industry, from loaded language to isolation tactics.

From the "No-NDA Paradox" to AWS bill forensics, here’s how investors separate real AI from Raspberry Pis in fancy cases.

We revisit 10 failed startups, from a $700 Wi-Fi juicer to an anonymous social app that turned toxic.